MAETZOLD DEREK J sold $519K of CSTL
MAETZOLD DEREK J (Pres. & Chief Exec. Officer) sold 17,144 shares of CASTLE BIOSCIENCES INC (CSTL) at an average of $30.28 ($30.15–$30.35, $0.52M total) across 2 trades over 2026-07-31 to 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The CEO’s open-market sale totals about $519k across two trades at roughly $30.15 to $30.35 per share, with holdings after the sale at 21,479 shares.
Market read
Traders may monitor insider activity for sentiment, but the 10b5-1 structure and lack of new fundamentals limit trading edge.
What to watch
The article does not disclose any new company-specific catalyst (earnings, trial results, guidance, or financing), so price impact should be treated as secondary.
Background
This is an SEC Form 4 insider transaction disclosure for Castle Biosciences, filed on 2026-08-04.
Ticker impact
Castle Biosciences CEO Maetzold sold $519,069 of CSTL shares via a 10b5-1 plan, reducing direct holdings to 21,479 shares.
Limited near-term impact expected; any reaction is likely sentiment-driven rather than fundamental.
Form 4 details an open-market sale with a stated 10b5-1 plan and no accompanying operational or financial guidance changes in the text.
Market effects
No sector-wide read-through is provided beyond a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerCASTLE BIOSCIENCES INC
US-listed biotechnology company, ticker CSTL.
- insiderMAETZOLD DEREK J
President and Chief Executive Officer who executed the reported sale.
